At the 2021 Society of Hematologic Oncology Annual Meeting, Greg Nowakowski, MD, of Mayo Clinic Rochester, discussed what to expect going forward in the field of aggressive B-cell lymphoma.
Post Tags:SOHO21
Related Posts
FDA shifts to real-time FAERS reporting, aiming to boost transparency in drug safety but raising concerns on data use.
The MZL cohort of a phase 2 study saw the most success from the atezolizumab plus obinutuzumab and venetoclax regimen.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
Glofitamab combos show high, durable responses in high-risk LBCL, per phase II COALITION trial in younger patients.
The name change will take effect on August 28, ahead of Blood Cancer Awareness Month in September.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.